Lipid-Lowering Agents: Targets Beyond PCSK9 (vol 124, pg 386, 2019)

被引：0
|
作者：
Hegele
机构：
来源：
CIRCULATION RESEARCH | 2020年 / 127卷 / 10期
关键词：
D O I：
10.1161/RES.0000000000000444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E251 / E251
页数：1
相关论文
共 50 条
  • [31] Immunity of lipid-lowering drugs - how statins and PCSK9 inhibition shape immune phenotype and function
    Schatzlmaier, P.
    Leutner, M.
    Wagner, L.
    Kautzky-Willer, A.
    Stockinger, H.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 350 - 350
  • [32] Economic Aspects of Lipid-Lowering Therapy Are PCSK9 Inhibitors cost-effective at their current Price?
    Schloegl, Haiko
    [J]. DIABETOLOGE, 2019, 15 (03): : 258 - 259
  • [33] Key aspects of PCSK9 inhibition beyond LDL lowering
    Ramin-Mangata, Stephane
    Blanchard, Valentin
    Lambert, Gilles
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (06) : 454 - 459
  • [34] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [35] Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Eze-timibe and PCSK9 Monoclonal Antibodies
    Ali, Adel Hajj
    Younis, Nour
    Abdallah, Rola
    Shaer, Farah
    Dakroub, Ali
    Ayoub, Mohammed Akli
    Iratni, Rabah
    Yassine, Hadi Mohamad
    Zibara, Kazem
    Orekhov, Alexander
    El-Yazbi, Ahmed Fawzy
    Eid, Ali H.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2021, 28 (36) : 7427 - 7445
  • [36] Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study
    Zhang, Yan
    Liu, Jun
    Li, Sha
    Xu, Ruixia
    Sun, Jing
    Li, Jianjun
    [J]. CARDIOLOGY, 2014, 129 : 29 - 29
  • [37] Lipid-lowering agents in secondary prevention after ischaemic stroke - how effective is our secondary prevention and is there a role for PCSK9 medication?
    Guyler, P.
    Muhammad, A.
    Haq, I.
    Vlahovic, I.
    [J]. CEREBROVASCULAR DISEASES, 2018, 45 : 250 - 250
  • [38] Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor (vol 545, pg 124, 2014)
    Wooten, Catherine J.
    Adcock, Audrey F.
    Agina-Obu, DaTonye I.
    Lopez, Dayami
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 562 : 122 - 122
  • [39] PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects
    Palee, Siripong
    McSweeney, Christian M.
    Maneechote, Chayodom
    Moisescu, Dalila M.
    Jaiwongkam, Thidarat
    Kerdphoo, Sasiwan
    Chattipakorn, Siriporn C.
    Chattipakorn, Nipon
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (11) : 7310 - 7319
  • [40] Lipid-Lowering Therapy and Intracerebral Hemorrhage Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
    Cuesta, Sanz Borja E.
    Saver, Jeffrey L.
    [J]. STROKE, 2021, 52
12345